Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1995-01-26
1998-03-31
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
4241781, 5303911, 5303913, 5303919, A61K 5110, A61K 3944, C07K 1600, C07K 1700
Patent
active
057335230
ABSTRACT:
The invention relates to novel labelled modified oligonucleotides useful for anti-sense therapy, a conjugate of a targeting moiety, such as an antibody and a modified oligonucleotide complementary to the labelled oligonucleotide, the combination of both being useful in therapy of viral infections, tumours and (auto)immunodiseases. Also disclosed are pharmaceutical formulations comprising the various compounds.
REFERENCES:
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 5045451 (1991-09-01), Uhr et al.
Chemical Reviews, vol. 90, No. 4, Jun. 1990, American Chemical Society, E. Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle".
Chemical Abstracts, vol. 112, No. 11, Mar., 1990, No. 95109K (Columbus, Ohio, US).
J.A. Fidanza et al., "Introduction of Reporter Groups at Specific Sites in DNA Containing Phosphorothioate Diesters," J.Am.Chem.Soc., 111, 1989, pp. 9117-9119.
Martindale, The Extra Pharmacopoeia, Ed. James Reynolds, 1989, p. 1380.
Canevari et al., Ann Oncol., vol. 5/8, pp. 698-901 (1994).
Hermentin, Behring Inst. Mitt, No. 82, pp. 197-215 (1988).
Kaspersen Franciscus M.
Kuijpers Wilhelmus H. A.
van Boeckel Constant A. A.
Achutamurthy Ponnathapura
Akzo Nobel N.V.
Gormley Mary E.
LandOfFree
Targeted delivery of a therapeutic entity using complementary ol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted delivery of a therapeutic entity using complementary ol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of a therapeutic entity using complementary ol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-48936